There are currently 105 active clinical trials seeking participants for Sickle Cell Disease research studies. The states with the highest number of trials for Autism participants are North Carolina, New York, California and Georgia.
Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia
Recruiting
MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2023
Locations: Magee Women's Hospital, Pittsburgh, Pennsylvania +4 locations
Conditions: Sickle Cell Disease
Age of Blood in Sickle Cell Transfusion
Recruiting
The Investigators hypothesize that older red cell units trigger phagocytosis and activation of circulating macrophages with a downstream immunomodulatory cascade and release of excess Non Transferrin Bound Iron(NTBI) that leads to increased rates of infection in adults with Sickle Cell Disease(SCD). To test this hypothesis, the study staff will perform a randomized prospective clinical trial. In aim 1, the study staff will determine the biochemical differences between ≥30 day-old versus ≤10 day... Read More
Gender:
All
Ages:
Between 16 years and 60 years
Trial Updated:
04/17/2023
Locations: Emory University, Atlanta, Georgia +2 locations
Conditions: Sickle Cell Disease
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
Recruiting
A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2023
Locations: University of Illinois at Chicago College of Medicine, Chicago, Illinois
Conditions: Sickle Cell Disease
Hydroxyurea Optimization Through Precision Study
Recruiting
Hydroxyurea Optimization through Precision Study (HOPS) is a prospective, multi-center, randomized trial that will directly compare a novel, individualized dosing strategy of hydroxyurea to standard weight-based dosing for children with SCA. The primary objective of the study is to evaluate whether a pharmacokinetics-based starting hydroxyurea dose thieves superior fetal hemoglobin response to to standard weight-based initial dosing. Patients will be recruited from the pediatric sickle cell clin... Read More
Gender:
All
Ages:
Between 6 months and 21 years
Trial Updated:
03/09/2023
Locations: Phoenix Children's Hospital, Phoenix, Arizona +13 locations
Conditions: Sickle Cell Disease, Sickle Cell Anemia
Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA
Recruiting
In this prospective, single-arm, open-label, imaging and treatment study, the investigator will test the hypothesis that crizanlizumab will prevent the progression of silent cerebral infarcts in patients with sickle cell disease. Study participants will undergo brain MRI before initiation of crizanlizumab and at 6 and 30 months after starting crizanlizumab infusions. The crizanlizumab cohort will be compared to a matched, observational cohort of patients not receiving crizanlizumab.
Gender:
All
Ages:
16 years and above
Trial Updated:
03/02/2023
Locations: Barnes-Jewish Hospital, Saint Louis, Missouri
Conditions: Sickle Cell Disease
Cerebral Oxygen Metabolism in Children
Recruiting
The purpose of this research study is to better understand how blood flow and metabolism change can influence brain development in the early decades of life. We will examine brain blood flow and metabolism using magnetic resonance imaging (MRI). The brain's blood vessels expand and constrict to regulate blood flow based on the brain's needs. The amount of expanding and contracting the blood vessels can do varies by age. The brain's blood flow changes in small ways during everyday activities, su... Read More
Gender:
All
Ages:
Between 3 years and 50 years
Trial Updated:
01/27/2023
Locations: Washington University of St. Louis, Saint Louis, Missouri
Conditions: Sickle Cell Disease, Cerebral Stroke
A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/22/2022
Locations: Sanguine Biosciences, Waltham, Massachusetts
Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Outcomes Mandate National Integration With Cannabis as Medicine
Recruiting
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Gender:
All
Ages:
7 years and above
Trial Updated:
05/29/2022
Locations: OMNI Medical Services, Boca Raton, Florida +16 locations
Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease
Recruiting
This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD).
Gender:
All
Ages:
Between 2 years and 25 years
Trial Updated:
03/02/2022
Locations: Children's National Health System, Washington, District of Columbia +5 locations
Conditions: Sickle Cell Disease